爱游戏平台注册登录
check quantity

Streptavidin AlphaPlex™ 645 (Sm) Acceptor Beads, 5 mg

The Streptavidin coated AlphaPlex™ 645 (Samarium) Acceptor beads are used to capture a wide variety of biotinylated reagents, ranging from small nucleotides to very large proteins. To avoid steric hindrance, it is recommended to use biotin derivatives including an aliphatic spacer composed of at least six carbons.

For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).

貨號
產品尺寸
AP125SM-C
250 µg
更多
AP125SM-M
5 mg
更多
AP125SM-R
25 mg
更多
Request Technical Support

請輸入有效數量

請登錄以添加收藏夾。

購物車為空

詳細信息

The Streptavidin coated AlphaPlex™ 645 (Samarium) Acceptor beads are used to capture a wide variety of biotinylated reagents, ranging from small nucleotides to very large proteins. To avoid steric hindrance, it is recommended to use biotin derivatives including an aliphatic spacer composed of at least six carbons. These beads can be used in conjunction with Alpha Donor beads to create no-wash assays for:


  • Protein-protein interactions
  • Protein-DNA interactions
  • Protein-RNA interactions
  • Protein-small molecule interactions
  • Analyte detection
  • Biomarker detection
  • Antibody detection
  • Enzymatic assays
  • Other immunoassays

  •  

 

AlphaPlex Acceptor beads are intended to be used in multiplexing assays, in conjunction with AlphaLISA Acceptor beads and Alpha Donor beads. In a typical Alpha assay, 1 mg of Acceptor beads is sufficient to run 1,000-2,000 wells using a 50 μL reaction volume.

規格

抗體偶聯物 Streptavidin
自動化兼容 Yes
珠型或核心珠型 AlphaPlex Samarium (645) Acceptor
檢測方法 Alpha
實驗類型 In vitro
Format Microplates
產品品牌名稱 AlphaPlex
包裝量 1.0 per pack
運輸條件 藍冰
產品尺寸 5 mg
資源
  • 所有

產品手冊

應用文獻

Development of Pharmacokinetic (PK) Assays for Detecting Biosimilars Targeting TNF alpha using AlphaLISA

Anti-inflammatory monoclonal antibody drugs that specifically target TNFα, such as Humira®, have been highly successful in the market. As patents expire on these top-selling drugs, effort has been placed on developing biosimilars. Biosimilars differ from small molecule generi ...

PDF 2 MB
Baidu
map